Daniel Woolson Sells 5,417 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) VP Daniel Woolson sold 5,417 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $181.33, for a total transaction of $982,264.61. Following the transaction, the vice president owned 17,062 shares of the company’s stock, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

ICU Medical Stock Performance

NASDAQ ICUI opened at $182.98 on Friday. The company has a market capitalization of $4.57 billion, a PE ratio of 155.07, a price-to-earnings-growth ratio of 2.56 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical, Inc. has a 52-week low of $112.50 and a 52-week high of $192.85. The company has a 50-day simple moving average of $156.56 and a 200 day simple moving average of $141.96.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. During the same period in the previous year, the company earned $2.10 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts predict that ICU Medical, Inc. will post 6.51 EPS for the current year.

Analyst Upgrades and Downgrades

ICUI has been the subject of several recent research reports. Raymond James Financial reissued a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a report on Friday, August 7th. Wall Street Zen raised shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Piper Sandler increased their target price on shares of ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $192.80.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in ICU Medical during the second quarter valued at $550,250,000. Jupiter Topco LLC bought a new position in ICU Medical in the 2nd quarter worth about $407,786,000. Millennium Management LLC increased its stake in ICU Medical by 173.4% in the 3rd quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock worth $130,638,000 after acquiring an additional 690,694 shares during the last quarter. Norges Bank purchased a new stake in shares of ICU Medical in the 4th quarter valued at about $58,083,000. Finally, Reinhart Partners LLC. purchased a new stake in shares of ICU Medical in the 2nd quarter valued at about $46,148,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.